What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

As we’ve been reporting, US Vice-President JD Vance says there is a “good chance” that the US and UK will come to a mutually ...

A report claimed that employees in the age group of 50-55 years working in Dr Reddy’s research and development (R&D) division ...

| Discover how AI and RWD are transforming drug development by optimizing clinical trial protocols, enhancing recruitment, ...

Pharma giant Dr Reddy’s Laboratories is reportedly cutting workforce-related costs by nearly 25%, signaling one of the most ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

And while Trump has criticized Ireland for attracting big pharma companies, he’s also suggested he wants to reshore ...